EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy

Richard Howley iD, Sharayu Chandratre, Bin Chen

Bioengineering · 21.04.2023 · 10 (4) · 496

DOI: 10.3390/bioengineering10040496 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 21.04.2023. Verfasst von Richard Howley und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA 19104, USA. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

5-Aminolevulinic acid (ALA) is a naturally occurring amino acid synthesized in all nucleated mammalian cells. As a porphyrin precursor, ALA is metabolized in the heme biosynthetic pathway to produce protoporphyrin IX (PpIX), a fluorophore and photosensitizing agent. ALA administered exogenously bypasses the rate-limit step in the pathway, resulting in PpIX accumulation in tumor tissues. Such tumor-selective PpIX disposition following ALA administration has been exploited for tumor fluorescence diagnosis and photodynamic therapy (PDT) with much success. Five ALA-based drugs have now received worldwide approval and are being used for managing very common human (pre)cancerous diseases such as actinic keratosis and basal cell carcinoma or guiding the surgery of bladder cancer and high-grade gliomas, making it the most successful drug discovery and development endeavor in PDT and photodiagnosis. The potential of ALA-induced PpIX as a fluorescent theranostic agent is, however, yet to be fully fulfilled. In this review, we would like to describe the heme biosynthesis pathway in which PpIX is produced from ALA and its derivatives, summarize current clinical applications of ALA-based drugs, and discuss strategies for enhancing ALA-induced PpIX fluorescence and PDT response. Our goal is two-fold: to highlight the successes of ALA-based drugs in clinical practice, and to stimulate the multidisciplinary collaboration that has brought the current success and will continue to usher in more landmark advances.

Schlagwörter

Stichwörter der Autor:innen

5-aminolevulinic acid (ALA)ATP-binding cassette subfamily G member 2 (ABCG2)ferrochelatase (FECH)fluorescence-guided tumor resectionheme biosynthesis enzymesphotodiagnosis (PD)photodynamic therapy (PDT)protoporphyrin IX (PpIX)theranostics

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA 19104, USA.
  • Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Richard Howley

Förderung

  • NCI NIH HHS
  • NIH

Zitieren

APA

Howley, R., Chandratre, S., & Chen, B. (2023). 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy. Bioengineering, 10(4), 496. https://doi.org/10.3390/bioengineering10040496

Vancouver

Howley R, Chandratre S, Chen B. 5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy. Bioengineering. 2023;10(4):496. doi:10.3390/bioengineering10040496

BibTeX
@article{Howley2023,
  author = {Howley, Richard and Chandratre, Sharayu and Chen, Bin},
  title = {5-Aminolevulinic Acid as a Theranostic Agent for Tumor Fluorescence Imaging and Photodynamic Therapy},
  journal = {Bioengineering},
  year = {2023},
  volume = {10},
  number = {4},
  pages = {496},
  doi = {10.3390/bioengineering10040496}
}
Kostenlos starten →